Recent News

• 12.03.2025 - The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
• 10.30.2025 - Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results
• 10.20.2025 - New One-Year Data Reinforcing the Robust and Sustained Efficacy of EMPAVELI® (pegcetacoplan) in C3G and Primary IC-MPGN to be Presented at ASN Kidney Week
• 10.16.2025 - Apellis Pharmaceuticals to Host Conference Call on October 30, 2025, to Discuss Third Quarter 2025 Financial Results

Recent Filings

• 11.18.2025 - 4 Statement of changes in beneficial ownership of securities
• 11.17.2025 - 144 Report of proposed sale of securities
• 11.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.07.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 10.30.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.23.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.21.2025 - 144 Report of proposed sale of securities
• 10.17.2025 - 4 Statement of changes in beneficial ownership of securities
• 10.16.2025 - 144 Report of proposed sale of securities
• 10.15.2025 - 4 Statement of changes in beneficial ownership of securities